All Title Author
Keywords Abstract

PLOS ONE  2009 

Type I Interferons and Interferon Regulatory Factors Regulate TNF-Related Apoptosis-Inducing Ligand (TRAIL) in HIV-1-Infected Macrophages

DOI: 10.1371/journal.pone.0005397

Full-Text   Cite this paper   Add to My Lib


TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that participates in HIV-1 pathogenesis through the depletion of CD4+ T cells. TRAIL is expressed on the cell membrane of peripheral immune cells and can be cleaved into a soluble, secreted form. The regulation of TRAIL in macrophages during HIV-1 infection is not completely understood. In this study, we investigated the mechanism(s) of TRAIL expression in HIV-1-infected macrophages, an important cell type in HIV-1 pathogenesis. A human monocyte-derived macrophage (MDM) culture system was infected with macrophage-tropic HIV-1ADA, HIV-1JR-FL, or HIV-1BAL strains. TRAIL, predominantly the membrane-bound form, increased following HIV-1 infection. We found that HIV-1 infection also induced interferon regulatory factor (IRF)-1, IRF-7 gene expression and signal transducers and activators of transcription 1 (STAT1) activation. Small interfering RNA knockdown of IRF-1 or IRF-7, but not IRF-3, reduced STAT1 activation and TRAIL expression. Furthermore, the upregulation of IRF-1, IRF-7, TRAIL, and the activation of STAT1 by HIV-1 infection was reduced by the treatment of type I interferon (IFN)-neutralizing antibodies. In addition, inhibition of STAT1 by fludarabine abolished IRF-1, IRF-7, and TRAIL upregulation. We conclude that IRF-1, IRF-7, type I IFNs, and STAT1 form a signaling feedback loop that is critical in regulating TRAIL expression in HIV-1-infected macrophages.


[1]  Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673–682.
[2]  Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, et al. (2004) TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877–889.
[3]  Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, et al. (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434: 88–93.
[4]  Ehrlich S, Infante-Duarte C, Seeger B, Zipp F (2003) Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24: 244–253.
[5]  Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, et al. (2005) TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 105: 2458–2464.
[6]  Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, et al. (1999) Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 162: 2639–2647.
[7]  Zhang M, Li X, Pang X, Ding L, Wood O, et al. (2001) Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. J Biomed Sci 8: 290–296.
[8]  Yang Y, Tikhonov I, Ruckwardt TJ, Djavani M, Zapata JC, et al. (2003) Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol 77: 6700–6708.
[9]  Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, et al. (2005) CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 106: 3524–3531.
[10]  Ryan LA, Peng H, Erichsen DA, Huang Y, Persidsky Y, et al. (2004) TNF-Related Apoptosis-Inducing Ligand Mediates Human Neuronal Apoptosis: Links to HIV-1 Associated Dementia. J Neuroimmunol 148: 127–139.
[11]  Huang Y, Erdmann N, Peng H, Herek S, Davis JS, et al. (2006) TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation. J Immunol 177: 2304–2313.
[12]  Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337–348.
[13]  Peng H, Huang Y, Duan Z, Erdmann N, Xu D, et al. (2005) Cellular IAP1 regulates TRAIL-induced apoptosis in human fetal cortical neural progenitor cells. J Neurosci Res 82: 295–305.
[14]  Gartner S, Popovic M (1990) Macrophage tropism of HIV-1. AIDS Res Hum Retroviruses 6: 1017–1021.
[15]  Gendelman HE, Orenstein JM, Baca LM, et al. (1989) The macrophage in the persistence and pathogenesis of HIV-1 infection. AIDS 3: 475–495.
[16]  Gabuzda DH, Ho DD, Monte MSDL, Rota TR, Sobel RA (1986) Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol 20: 289–295.
[17]  Gartner S, Markovits P, Markovits DM, Kaplan MH, Gallo RC, et al. (1986) The role of mononuclear phagocytes in HTLV-III LAV infection. Science 233: 214–218.
[18]  Koenig S, Gendelman HE, Orenstein JM, Canto MCD, Pezeshkpour GH, et al. (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089–1093.
[19]  Shieh JTC, Albright AV, Sharron M, Gartner S, Strizki J, et al. (1998) Chemokine Receptor Utilization by Human Immundeficiency Virus Type 1 Isolates That Replicate in Microglia. J Virol 72: 4243–4249.
[20]  Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, et al. (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL. J Exp Med 189: 1343–1354.
[21]  Gong B, Almasan A (2000) Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 278: 747–752.
[22]  Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, et al. (2005) Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 102: 13974–13979.
[23]  Gessani S, Puddu P, Varano B, Borghi P, Conti L, et al. (1994) Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication. J Virol 68: 1983–1986.
[24]  Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835–1837.
[25]  Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y (2001) Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev 12: 337–348.
[26]  Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415–1421.
[27]  Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662.
[28]  Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, et al. (2001) Antiviral responses by natural killer cells through TRAIL induction by interferon-alpha/beta. Eur J Immunology 31: 3138–3146.
[29]  Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, et al. (1992) Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 12: 3315–3324.
[30]  Lohoff M, Ferrick D, Mittrucker HW, Duncan GS, Bischof S, et al. (1997) Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6: 681–689.
[31]  Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, et al. (2000) Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13: 539–548.
[32]  Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772–777.
[33]  Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, et al. (1988) Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54: 903–913.
[34]  Abbate I, Dianzani F, Capobianchi MR (2000) Activation of signal transduction and apoptosis in healthy lymphomonocytes exposed to bystander HIV-1-infected cells. Clin Exp Immunol 122: 374–380.
[35]  Battistini A, Marsili G, Sgarbanti M, Ensoli B, Hiscott J (2002) IRF regulation of HIV-1 long terminal repeat activity. J Interferon Cytokine Res 22: 27–37.
[36]  Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Kruhlak MJ, et al. (2006) Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci U S A 103: 7000–7005.
[37]  Honda K, Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6: 644–658.
[38]  Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H (2004) Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. Embo J 23: 3051–3060.
[39]  Park SY, Seol JW, Lee YJ, Cho JH, Kang HS, et al. (2004) IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 271: 4222–4228.
[40]  Kirshner JR, Karpova AY, Kops M, Howley PM (2005) Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol 79: 9320–9324.
[41]  Romieu-Mourez R, Solis M, Nardin A, Goubau D, Baron-Bodo V, et al. (2006) Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res 66: 10576–10585.
[42]  Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, et al. (1988) Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 167: 1428–1441.
[43]  Cotter RL, Zheng J, Che M, Niemann D, Liu Y, et al. (2001) Regulation of Human Immunodeficiency Virus Type 1 Infection, beta- Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry. J Virol 75: 4308–4320.
[44]  Lin R, Heylbroeck C, Genin P, Pitha PM, Hiscott J (1999) Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription. Mol Cell Biol 19: 959–966.
[45]  Esser R, Glienke W, von Briesen H, Rubsamen-Waigmann H, Andreesen R (1996) Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 88: 3474–3481.
[46]  Zhao ML, Kim MO, Morgello S, Lee SC (2001) Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J Neuroimmunol 115: 182–191.
[47]  Halaas O, Vik R, Ashkenazi A, Espevik T (2000) Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 51: 244–250.
[48]  Durbin JE, Hackenmiller R, Simon MC, Levy DE (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443–450.
[49]  Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, et al. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431–442.
[50]  Frank DA, Mahajan S, Ritz J (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 5: 444–447.
[51]  Tamura T, Yanai H, Savitsky D, Taniguchi T (2008) The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26: 535–584.
[52]  Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, et al. (2002) Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 195: 1359–1370.
[53]  Sgarbanti M, Remoli AL, Marsili G, Ridolfi B, Borsetti A, et al. (2008) IRF-1 Is Required for Full NF-{kappa}B Transcriptional Activity at the HIV-1 LTR Enhancer. J Virol.
[54]  Takeuchi O, Akira S (2009) Innate immunity to virus infection. Immunol Rev 227: 75–86.
[55]  Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM (2008) HIV-1 activates macrophages independent of Toll-like receptors. PLoS ONE 3: e3664.
[56]  Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, et al. (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23: 19–28.
[57]  Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, et al. (2005) Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175: 2851–2858.
[58]  Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730–737.
[59]  Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101–105.
[60]  Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, et al. (2008) HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 373: 85–97.
[61]  Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, et al. (2006) Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc Natl Acad Sci U S A 103: 15136–15141.
[62]  Szebeni J, Dieffenbach C, Wahl SM, Venkateshan CN, Yeh A, et al. (1991) Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures. J Virol 65: 6362–6364.
[63]  Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, et al. (1997) Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Defic Syndr Hum Retrovirol 16: 247–253.
[64]  Bovolenta C, Camorali L, Lorini AL, Ghezzi S, Vicenzi E, et al. (1999) Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 94: 4202–4209.
[65]  Federico M, Percario Z, Olivetta E, Fiorucci G, Muratori C, et al. (2001) HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 98: 2752–2761.
[66]  Wen Z, Zhong Z, Darnell JE Jr (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241–250.
[67]  Li X, Leung S, Qureshi S, Darnell JE Jr, Stark GR (1996) Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha. J Biol Chem 271: 5790–5794.
[68]  Marie I, Durbin JE, Levy DE (1998) Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. Embo J 17: 6660–6669.
[69]  Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, et al. (1998) Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 441: 106–110.
[70]  Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O (1995) Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 13: 369–398.
[71]  Leaman DW, Leung S, Li X, Stark GR (1996) Regulation of STAT-dependent pathways by growth factors and cytokines. Faseb J 10: 1578–1588.
[72]  Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2): 297–314.
[73]  Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, et al. (2004) IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood.


comments powered by Disqus